Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Acknowledgment of Support

This activity is supported by an educational grant from Puma Biotechnology, Inc.

HER2-Positive Breast Cancer Tumor Board: Aligning Patient and Evidence to Inform Sequencing Decisions in Early and Advanced Disease Real World Care Scenarios

Release Date: June 30, 2021
Expiration Date: June 30, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in treatment strategies for patients with HER2-positive breast cancer. In this educational program, these experts review the latest clinical data in HER2-positive breast cancer, set in the context of real-world clinical scenarios, as they respond to prerecorded cases described by community oncologists and fellows.

This educational activity is an archive of the live virtual symposium held on June 16, 2021.

Acknowledgement of Commercial Support

This activity is supported by an educational grant from Puma Biotechnology, Inc.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward medical, surgical, and radiation oncologists interested in the treatment of breast cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment and management of patients with breast cancer are also welcomed to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain expert guidelines regarding the determination of HER2 status as well as criteria for risk assessment
  • Discuss evidence from landmark clinical trials evaluating HER2-targeted therapies in patients with early-stage and metastatic HER2+ breast cancers
  • Integrate clinical data and expert guidelines into evidence-based treatment plans to individualize therapy for patients with early-stage or advanced/metastatic HER2+ breast cancer, including those with HER2+ brain metastases
  • Incorporate strategies for minimizing, mitigating, or managing adverse events associated with HER2-targeted therapies to optimize outcomes

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource®, LLC, have no relevant financial relationships with ineligible entities.

Program Chair

Hope S. Rugo, MD, FASCO
Hope S. Rugo, MD, FASCO
Professor of Medicine
Director, Breast Oncology and Clinical Trials Education
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, CA

Disclosures: Grant/Research Support: AstraZeneca; Daiichi Sankyo Company, Ltd; Eisai Co, Ltd; Genentech/Roche; Immunomedics; Lilly; MacroGenics; Merck; Novartis AG; OBI Pharma, Inc; Odonate Therapeutics, Inc; Pfizer; Seattle Genetics, Inc; Sermonix Pharmaceuticals Inc; Other: Mylan N.V.; Puma Biotechnology; Samsung Biologics.


William J. Gradishar, MD, FASCO, FACP
William J. Gradishar, MD, FASCO, FACP
Professor of Medicine
Betsy Bramsen Professor of Breast Oncology
Chief, Division of Hematology and Oncology
Deputy Director, Clinical Network
Director, Maggie Daley Center for Women’s Cancer Care
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Northwestern University Feinberg School of Medicine
Chicago, IL

Disclosures: Grant/Research Support: Genentech/Roche; Consultant: Daiichi Sankyo; DMC-Seattle Genetics, Inc; Genentech; Immunomedics.

Ian Krop, MD, PhD
Ian Krop, MD, PhD
Associate Chief, Division of Breast Oncology
Senior Physician
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Grant/Research Support: Genentech/Roche; Pfizer; Consultant: Bristol Myers Squibb; Context Therapeutics Inc; Daiichi Sankyo Company, Ltd; Genentech/Roche; MacroGenics, Inc; Merck; Novartis AG; Taiho Oncology, Inc.

Debu Tripathy, MD
Debu Tripathy, MD
Professor and Chair
Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center
Houston, TX

Disclosures: Grant/Research Support: Novartis AG; Polyphor Ltd; Consultant: AstraZeneca; Exact Sciences Corp; Gilead Sciences, Inc; GlaxoSmithKline; Novartis AG; OncoPep, Inc; Pfizer.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By